Abbonarsi

First fatal intoxication involving ivabradine - 27/04/19

Doi : 10.1016/j.toxac.2019.03.048 
A. Knapp-Gisclon 1, , C. Mayer-Duverneuil 1, C. Rambaud 2, J.-C. Alvarez 1
1 Pharmacologie/toxicologie, CHU R.-Poincaré, AP–HP, Garches, France 
2 Service de médecine légale, CHU R.-Poincaré, AP–HP, Garches, France 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Objective

To present a fatal intoxication involving Ivabradine.

Case history

A 61-year-old woman was admitted to hospital for voluntary intoxication. At admission, the patient presented drowsiness. Few hours later she suffered a cardiac arrest followed by a successful resuscitation but she died 10hours after admission. Autopsy and reference toxicological analysis were performed.

Methods

HPLC-DAD, GC-MS and LC-MS/MS screening were performed. Quantification was achieved by LC-MS/MS (TSQ Vantage ThermoFischer®), after a double liquid/liquid extraction under alkaline condition [hexane/ethyl acetate (1/1, v/v) followed by Chloroform/Isopropanol (80/20, v/v)]. Chromatographic separation was achieved using a Hypersyl gold PFP column and a classic acetonitrile/formiate2mM, 0.1% formic acid buffer gradient. IS used was morphine D3.

Results

The method was fully validated in whole blood. Calibration curves were linear from 5 to 500ng/mL. The LOQ was 5ng/mL and the intra- and inter-assays bias were all acceptable (<15%). Ivabradine was found and quantified in every matrix. Results are listed in the Table 1. Due to high concentrations, samples were diluted 1:2 and 1:10. Midazolam, atropine and atracurium metabolite (laudanosine) were identified at therapeutic concentrations. Pregabalin, zopiclone and N-desmethylzopiclone were found at 50μg/mL (therapeutic range: 2–8μg/mL), 206ng/mL (therapeutic range: 10–50ng/mL) and 400ng/mL.

Discussion

Midazolam, atropine and atracurium were administered during hospitalization, while ivabradine, zopiclone and pregabalin were part of her chronic treatment. Ivabradine is indicated in the management of stable angina pectoralis and symptomatic chronic heart failure. It selectively and specifically inhibits the pacemaker current I(f) thereby slowing heart rates with a dose dependent activity. There are few data about therapeutic concentrations; they appear to be around 10ng/mL, with a Cmax of 22ng/mL. Three non-fatal Ivabradine intoxications were reported in which peripheral blood concentrations were 119ng/mL [1], 375ng/mL [2] and 525ng/mL [3]. The concentration in our case is much higher and probably played a major role in the occurrence of the death.

Conclusion

We describe here the first case of a fatal intoxication involving Ivabradine; we furthermore provide postmortem concentrations in organs.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2019  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 31 - N° 2S

P. S37 - Maggio 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Fatal intoxication with Kratom: A case report
  • J. Bourgine, C. Garnier-Jardin, B. Chrétien, R. Le Boisselier, M. Loilier, V. Lelong-Boulouard, A. Cesbron
| Articolo seguente Articolo seguente
  • MDMA-related deaths: About 3 cases
  • J. Becam, J.-M. Gaulier, V. Baillif-Couniou, C. Sastre, M.-D. Piercecchi, G. Leonetti, A.-L. Pélissier-Alicot

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.